Danske Bank’s Damora Therapeutics, Inc. Ordinary Shares DMRA Stock Holding History

Danske Bank’s Portfolio DMRA Stock Details DMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-7	Closed	-$85	–	1500
2024 Q3	$85	Buy	+7	New	+$91	﹤0.01%	1463

Other funds holding DMRA

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Danske Bank's DMRA Position: Q4 2024 in Review

Danske Bank sold out of Damora Therapeutics, Inc. Ordinary Shares (DMRA) in Q4 2024, closing a stake of 7 shares — an estimated $85 sold.

Danske Bank first reported a position in DMRA in Q3 2024 and held it in 1 quarter. The position peaked at $85 in Q3 2024. 10 funds tracked by Wall St. Rank hold DMRA as of Q4 2024.

Danske Bank reported no remaining Damora Therapeutics, Inc. Ordinary Shares position as of Q4 2024 after selling out during the quarter.
Danske Bank sold 7 Damora Therapeutics, Inc. Ordinary Shares shares in Q4 2024, an estimated $85.
Danske Bank first reported a position in Damora Therapeutics, Inc. Ordinary Shares in Q3 2024 and held it in 1 quarter.
Danske Bank's Damora Therapeutics, Inc. Ordinary Shares position peaked at $85 in Q3 2024.
10 funds tracked by Wall St. Rank held Damora Therapeutics, Inc. Ordinary Shares as of Q4 2024.

Based on Danske Bank's 13F filing for Q4 2024, filed 18 Mar 2026.